A trading update from mass spectrometry equipment company Microsaic Systems (MSYS) commences that “revenues for FY21 have significantly exceeded those of FY20, recovering to a level slightly ahead of that in FY19, a pre-pandemic benchmark” and includes CEO Glenn Tracey “absolutely delighted”. So what of a current share price response down to around 0.19p?...
The CEO of Microsaic Systems (MSYS) Glenn Tracey is “thrilled to report this transformational performance for the first half of 2021”. The shares have responded to the half-year results announcement to currently 0.22p, more than 12% lower! So what’s going on?...
On 22nd December Microsaic Systems (MSYS) announced that it had appointed KRE Corporate Recovery “to explore other remaining options to maximise value for creditors and potentially other stakeholders”. It was “other remaining options” as a formal sale process had failed – and the shares fell back. However, they have recently significantly recovered and now a further statement from the company has been required...
Shares in Microsaic Systems (MSYS) are down by 60% today. Mr Market is showing Christmas generosity, this stock is still anywhere between 60% and 100% too high...
“Microsaic Systems plc (MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce its unaudited interim results for the six months ended 30 June 2020 and an update on trading since the period end”. Encouraging then?...
Previously writing on Microsaic Systems (MSYS), in March with the shares at 0.80p I concluded it’s not the board’s belief which is important here and note the fundraising is required following the above financials and from a current £3.65 million market cap. Readers here should not be surprised by this latest and, natch, currently the stance remains avoid / sell. Now a “Strategic Review and Formal Sale Process” announcement – and the shares 0.35p...
“Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce its audited financial results for the year ended 31 December 2019”. The shares have currently responded to 0.80p – 20% lower!…
Microsaic Systems (MSYS) “is pleased to announce the appointment of WH Ireland Limited as Joint Broker with immediate effect, alongside N+1Singer as Nominated Adviser and Joint Broker”. Hmmm – I wonder why?...
Previously writing on developer of mass spectrometry instruments Microsaic Systems (MSYS) it was with the company arguing “encouraged with the progress made in the first half” but the shares down to 1.15p. They have since fallen further and today a “Global collaboration agreement with Axcend Corp”…
“Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce its unaudited interim results for the six months ended 30 June 2019”. The shares have currently responded to 1.15p – er, more than 25% lower!...
An intra-day (11:20am) “Bioprocessing partnership update & trading update” from mass spectrometry instruments developer Microsaic Systems (MSYS). This firstly “confirms that trading in 2018 remains in line with the board's expectations” and then that phase two of the partnership “with a global partner in bioprocessing… has now been completed successfully, with a clear addressable market identified and positive feedback received from potential customers”. So why a 25% share price fall, towards 1p?...
A “Trading Statement” announcement from Microsaic Systems (MSYS) includes Chairman Eric Yeatman commenting “we are very encouraged with the progress since our 21 March 2017 update, when we introduced our biopharma strategy, specifically around bioprocessing. We are engaging with several of the leading players in the global market for bioprocessing equipment”. However, the statement also includes that “the company now expects its H1 and full year 2017 revenue to be significantly lower than for 2016”. Hmmm…
A “Trading Statement” announcement from Microsaic Systems (MSYS) starts with that “it is expected that EBITDA and pre-tax profit for 2016 will be broadly in line with market expectations… The company has reshaped its business strategy to focus on the Pharma market where clear opportunities exist for the company's products”. Hmmm, “broadly in line” is of course ‘slightly behind’, though at least there’s “clear opportunities” ahead. Though, wait. What’s that? The shares currently down approaching 20%, towards 3p?!? …
